Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
T cell receptor alpha joining 42 (TRAJ42)
- Target
- TRAJ42
- Molecular classification
- Other (T cell receptor joining gene segment; not a functional receptor, enzyme, transporter, etc.)
01
Overview
T cell receptor alpha joining 42 (TRAJ42) is a gene segment part of the T cell receptor (TCR) alpha locus, specifically a joining (J) gene segment involved in the somatic recombination process that generates TCR diversity[3][2]. It does not encode a standalone protein, receptor, or druggable target; rather, it contributes to the formation of the TCR alpha chain when fused with variable (V) segments during T cell development[3]. Recent research has found that TRAJ42 is recurrently used in the TCR alpha chains of certain MR1-restricted, cancer-reactive T cells, which may have implications for cancer immunology studies, but it is not a direct therapeutic target[1].
- Other names
- TRAJ42T cell receptor alpha joining 42
02
Mechanism of action
None (TRAJ42 is not a druggable receptor or protein but a gene segment incorporated into TCR alpha chains)
03
Biological functions
Generation of T cell receptor (TCR) diversity through V(D)J recombination
04
Disease associations
None directly; however, the gene segment is recurrently used in MR1-restricted, cancer-reactive T cells, suggesting a potential indirect implication in immune responses to cancer
05
Safety considerations
None (TRAJ42 is not a therapeutic target or drug receptor)
06
Biomarkers
TRAJ42 usage acts as a marker for certain MR1-restricted, cancer-reactive T cell populations (could be used for research purposes as a fingerprint for such TCRs)
Beyond the preview
Go deeper on T cell receptor alpha joining 42 (TRAJ42).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on T cell receptor alpha joining 42 (TRAJ42).